Dasatinib: for some difficult cases of adult leukaemia.
D000328:Adult; D002986:Clinical Trials as Topic; D017277:Drug Approval; D005060:Europe; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D009965:Orphan Drug Production; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles